All Teva articles
-
BusinessSartan contaminant recall hits generics manufacturers
Three European suppliers recalling multiple batches of medicines owing to active ingredient contamination
-
BusinessLandmark ruling in Oklahoma opioid lawsuit
J&J judged responsible for ‘public nuisance’ in first case to go to trial
-
NewsApotex chief executive steps down amid tumult at generics firm
President and chief executive of Canada’s biggest generic drugmaker resigns the same day that police announce its founder and his wife were murdered
-
BusinessTeva to cut 14,000 jobs
Saddled with debt in an increasingly competitive generic drug industry, the Israel-headquartered giant begins a difficult transformation
-
BusinessFederal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
-
BusinessAmgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
-
BusinessUS probes opioid manufacturers
Attorneys general from 41 states will investigate companies over alleged fraudulent marketing and distribution of painkillers
-
BusinessTeva to sell off women’s health businesses for $1.4bn
Deals continue Teva’s bid to get rid of non-core businesses and raise cash to service its debts
-
BusinessTeva sells off contraceptive device in $1.1bn deal
CooperSurgical to acquire Paragard as Teva seeks to offload assets
-
BusinessTakeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses
-
BusinessTeva hit with fines and patent loss
Double whammy as firm settles subsidiary pay-for-delay suit and courts invalidate patents on multiple sclerosis drug
-
BusinessTeva fined $520m for corruption
World’s largest generics manufacturer admits paying bribes in Russia, Ukraine and Mexico
-
BusinessIndia’s Intas bags UK and Irish generics
Teva sheds former Actavis business to satisfy competition requirements of its Allergan generics takeover
-
Business
Teva sells off products in preparation for Allergan merger
Generics deals with Impax, Dr Reddy’s and Sagent aimed at satisfying competition authorities
-
Business
Heptares takes on new partners for drug discovery
Firm set to receive over $1bn from research partnerships
-
Business
Perrigo nabs US rights to AZ Crohn’s drug
Irish generics maker evades Mylan takeover bid and expands gastroenterology portfolio
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Allergan steps away from generics with sale to Teva
$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top 10
-
Business
Teva fined $1.2bn in pay-for-delay case
Company illegally blocked generic competition of sleep disorder drug, and settlement terms tighten up rules on anticompetitive behaviour
-
BusinessGenerics firms in three-way takeover battle
Mylan is chasing Perrigo, while fending off advances from Teva